Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Rating of “Buy” by Brokerages

Century Therapeutics, Inc. (NASDAQ:IPSC) has received a consensus recommendation of “Buy” from the six research firms that are currently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $10.00.

A number of research analysts recently commented on the stock. Guggenheim reiterated a “buy” rating on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Piper Sandler decreased their price target on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research note on Monday, December 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Century Therapeutics in a research note on Wednesday, January 22nd.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in IPSC. Casdin Capital LLC grew its position in shares of Century Therapeutics by 61.6% during the 4th quarter. Casdin Capital LLC now owns 5,190,506 shares of the company’s stock worth $5,242,000 after purchasing an additional 1,978,190 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Century Therapeutics by 1,041.8% during the 4th quarter. Millennium Management LLC now owns 1,607,174 shares of the company’s stock worth $1,623,000 after acquiring an additional 1,466,415 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Century Therapeutics by 146.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,202,885 shares of the company’s stock worth $1,215,000 after acquiring an additional 714,685 shares during the period. Deutsche Bank AG lifted its holdings in shares of Century Therapeutics by 890.7% during the 4th quarter. Deutsche Bank AG now owns 193,368 shares of the company’s stock worth $195,000 after acquiring an additional 173,849 shares during the period. Finally, Wellington Management Group LLP bought a new stake in shares of Century Therapeutics during the 3rd quarter worth approximately $284,000. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Stock Performance

Shares of IPSC opened at $0.60 on Thursday. Century Therapeutics has a 52 week low of $0.57 and a 52 week high of $5.24. The firm has a market cap of $51.07 million, a P/E ratio of -0.32 and a beta of 1.75. The firm’s 50-day simple moving average is $0.81 and its 200 day simple moving average is $1.22.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.